Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Everolimus plus Glivec in Glivec-resistant progressive GIST
2005-004837-16Phase 2Completed
- Sponsor
- Novartis
- Start
- Sep 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of everolimus and imatinib in gastrointestinal stromal tumor (GIST), sponsored by Novartis. Primary endpoint: Progression-free survival at 4 months. Started Sep 2006; status: completed.
02
Drugs
everolimusimatinib
03
Conditions
gastrointestinal stromal tumor (GIST)
Beyond the preview
Go deeper on 2005-004837-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-004837-16.